Evidence map›Paper›PMID 24991411›Full record

ArticleBiomarker research2014

CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Keyur Thakar, Aileen Novero, Arundhati Das, Adriana Lisinschi, Bella Mehta, Tauseef Ahmed, Delong Liu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Keyur ThakarDivision of Hematology & Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA.
Aileen NoveroDivision of Hematology & Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA.
Arundhati DasDivision of Hematology & Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA.
Adriana LisinschiDivision of Hematology & Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA.
Bella MehtaDivision of Hematology & Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA.
Tauseef AhmedDivision of Hematology & Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA.
Delong LiuHenan Tumor Hospital, Zhengzhou University, Zhengzhou 450003, China.
Westchester Medical Center · USZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) remains the most commonly used front-line therapy for Hodgkin lymphoma. However, atypical and extranodal presentations present challenges to initial therapy, especially in the presence of renal and liver failure. We hereby present two cases of young male patients with atypical presentation of Hodgkin lymphoma with severe abnormal liver function. Patients showed excellent response to cyclophosphamide, etoposide, procarbazine and prednisone (CEPP regimen).

Indexed as

CEPP regimenextranodal lymphomaHodgkin lymphoma

Identifiers

PMID24991411
PMCPMC4078319
OpenAlexW2111620607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.